Topiramate Capsule, Extended Release
Product Images NDC 43598-940

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 43598-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy�s Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Topiramate Extended-Release Capsules 25 mg label showing a container with 30 capsules. The label indicates Rx only, directions to swallow capsule whole, and contains storage and handling instructions. The product is distributed by Dr. Reddy's Laboratories Inc., made in India, with a capsule described as having an orange body and pink cap.*

FDA Label Image

Container2 (Container2)

Topiramate Extended-Release Capsules 50 mg label for 30 capsules by Dr. Reddy's Laboratories Inc. The label specifies oral use with instructions to swallow whole and details the capsule's pink opaque body with yellow opaque cap. Storage, handling, and packaging information including barcode and distributor address are visible.*

FDA Label Image

Container3 (Container3)

Label for Topiramate Extended-Release Capsules 100 mg by Dr. Reddy's Laboratories Inc. The label states once daily dosage, contains 30 capsules, and instructs to swallow capsules whole and intact. Capsules have a blue opaque body and light green opaque cap. Storage details, distributor information, and a barcode are also included.*

FDA Label Image

Container4 (Container4)

Packaging label for Topiramate Extended-Release Capsules, 200 mg by Dr. Reddy's Laboratories Inc. The label shows the dosage form as hard gelatin capsules with a green opaque body and brown opaque cap. It contains 30 capsules and includes storage instructions, a barcode, and distributor information, indicating the product is made in India and is for prescription use only.*

FDA Label Image

Figure1 (Figure1)

This is a line graph showing cumulative rates for time to first seizure over a period of up to 500 days. Two dosage groups of Topiramate, 50 mg/day and 400 mg/day, are compared with separate lines. The x-axis represents time in days, and the y-axis shows cumulative seizure rates, with the 50 mg/day group having higher rates than the 400 mg/day group.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate with placebo and topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day across two studies. The chart shows a dose-dependent decrease in migraine rate, with statistical significance indicated for higher doses.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient Topiramate, showing its molecular arrangement with rings and functional groups including methyl and sulfonamide moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.